IMCR(Immunocore Holdings plc) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $36.48M | $174.36M | $249.43M | $310.20M | $400.02M |
| 毛利润 | $36.48M | $173.27M | $248.39M | $307.47M | $394.93M |
| 营业利润 | −$174.59M | −$51.71M | −$59.65M | −$70.46M | −$45.35M |
| 净利润 | −$180.03M | −$52.54M | −$55.29M | −$51.09M | −$35.51M |
| 经营现金流 | −$143.11M | −$49.21M | $2.94M | $26.06M | −$10.71M |
| 自由现金流 | −$144.49M | −$51.41M | −$2.48M | $20.89M | −$15.05M |
| 摊薄每股收益 | $-4.24 | $-1.15 | $-1.13 | $-1.02 | $-0.71 |